Nat Genet:肺部黏蛋白是调节新冠病毒感染的宿主因子——向新抗病毒疗法迈进

2022-08-01 转化医学网 转化医学网

团队发现,肺细胞膜中的粘蛋白MUC1和MUC4可以保护肺细胞免受感染。

导读:

近日,有研究表明,我们体内的特定蛋白质可以促进或保护我们免受SARS-CoV-2感染,这有望为新的抗病毒疗法打开大门。研究人员使用CRISPR技术测试了每个人类基因对人类肺细胞中SARS-CoV-2感染的影响。他们发现,黏蛋白——肺部黏液的主要成分——似乎有助于阻止SARS-CoV-2病毒进入我们的细胞。

最近,科学家们在探索肺细胞和导致新冠肺炎的SARS-CoV-2病毒之间的微观战斗方面迈出了重要的一步。加州大学伯克利分校领导的一项研究发现,我们体内的特定蛋白质可以促进或保护我们免受SARS-CoV-2感染,这有望为新的抗病毒疗法打开大门。

这项研究于本周发表在《Nature Genetics》杂志上,研究人员使用CRISPR技术测试了每个人类基因对人类肺细胞中SARS-CoV-2感染的影响。他们揭示了病毒依赖于感染细胞的新途径,以及帮助保护免受病毒感染的抗病毒途径。值得注意的是,黏蛋白——肺部黏液的主要成分——似乎有助于阻止SARS-CoV-2病毒进入我们的细胞。

该研究的共同主要作者、加州大学伯克利分校公共卫生学院 Eva Harris实验室的博士后研究员Scott Biering说:“我们的数据表明,粘蛋白作为一种屏障,对限制SARS-CoV-2感染发挥着关键作用,它是试图进入我们肺部上皮细胞的病毒的屏障。此外,个人肺部的粘蛋白表达水平也可能会影响COVID-19疾病的进展。”

这项研究汇集了来自10个机构的研究人员,Arc研究所的联合创始人Patrick Hsu是该研究的首席研究员。加州大学伯克利分校公共卫生教授Harris和斯坦福大学医学院助理教授 Silvana Konermann是这项研究的资深合著者。其他合作者来自斯坦福大学、北卡罗来纳大学教堂山分校、耶鲁大学医学院和康奈尔大学,涉及免疫学、生物工程、流行病学、分子生物学和遗传学等学科。

研究人员一起试图确定SARS-CoV-2病毒是如何进入人类细胞并在患病期间如此高效地复制的。他们还试图确定人类细胞中有潜力能对抗感染的特定防御机制,这有望激发新的治疗策略。

640

https://www.nature.com/articles/s41588-022-01131-x

复杂的黏蛋白

团队发现,肺细胞膜中的粘蛋白MUC1和MUC4可以保护肺细胞免受感染。这个发现令人惊讶,因为此前的研究表明,黏液堆积可能是一些人患上covid -19重症的原因(黏液会使人呼吸困难),并建议使用药物耗尽黏液。

然而,黏蛋白是复杂的,需要更多的研究来完全了解它们。研究人员发现,其他分泌到肺部黏液层的粘蛋白——MUC5AC 和MUC5B,不仅无法阻止SARS-CoV-2感染,甚至有时会促进病毒感染。Biering表示,每个人产生的粘液类型和数量可能会导致不同的SARS-CoV-2感染结果,并导致不同的治疗策略。“能够产生大量正确类型的粘液的人可能会受到很好的保护。但那些产生大量错误类型粘液的人可能会有较大的感染风险,而那些只产生少量正确类型的人也可能面临较大的风险。”

这也是研究人员研究SARS-CoV-2病毒如何与人类肺细胞相互作用的第一项研究,标志着COVID-19研究的关键进展。

“众所周知,我们自身的蛋白质可以促进或抑制病毒感染,”Biering说,“但这是首次在人肺上皮细胞中对这些宿主细胞蛋白进行系统研究,以应对SARS-CoV-2感染。”

过去对SARS-CoV-2感染的研究中,使用的细胞类型不天然含有肺部感染病毒的受体或其他途径。在这项研究中,研究人员希望使用一种更有关联的细胞类型,即位于肺内表面的名为Calu-3的人类上皮细胞,以设法对人类SARS-CoV-2感染涉及的生物学有更准确的了解。

全基因组CRISPR

研究人员进行了全基因组CRISPR功能获得和功能丧失筛选,以消除或过表达人类基因组中的每一个基因。然后,他们测量了这些基因表达变化对人肺上皮细胞中SARS-CoV-2感染的影响。

Hsu说:“你可以在人类细胞上进行大规模并行的‘饥饿游戏’式的实验,看看当病毒感染肺部细胞时,你可以改变哪些基因来调整它们的生存或生长能力。”

研究人员的筛选成功地识别了数百个对SARS-CoV-2复制至关重要的基因,以及数百个可以限制SARS-CoV-2的基因。他们将黏蛋白确定为细胞感染的关键限制因素,不论在小鼠模型还是人类中。他们还研究了粘蛋白如何与其他呼吸道病毒相互作用,包括甲型流感病毒、人类副流感病毒、普通感冒冠状病毒和呼吸道合胞病毒。与SARS-CoV-2一样,结果是不可预测的。“我们展示的是黏蛋白广义上是抗病毒的,但实际情况要复杂得多,”Hsu说,“事实上,在一些病毒中,我们发现黏蛋白过度表达实际上似乎增加了传染性。”

更好地理解病毒与粘蛋白的相互作用在未来的工作中至关重要,目前的发现为之提供了一个很好的起点。Sarnik说:“这项研究帮助我们更多地了解这种病毒,并为进一步研究可药物靶点开辟了新途径。”

参考资料:

https://medicalxpress.com/news/2022-07-human-lung-proteins-advance-thwart.html

注:本文旨在介绍医学研究进展,不能作为治疗方案参考。如需获得健康指导,请至正规医院就诊。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-09-02 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-09-30 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-09-21 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-02 yahu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-02 wincls
  7. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-01 ms5000000518166734

    学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-01 涧西源长

    感谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1885903, encodeId=55321885903cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 02 08:30:06 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049415, encodeId=875e204941500, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Sep 30 04:30:06 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734528, encodeId=21ac1e345280b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Sep 21 15:30:06 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686393, encodeId=c440168639371, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Nov 28 11:30:06 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292570, encodeId=b8c212925e097, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404789, encodeId=b98b1404e893f, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530824, encodeId=9cdb1530824dc, content=<a href='/topic/show?id=3f135548128' target=_blank style='color:#2F92EE;'>#抗病毒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55481, encryptionId=3f135548128, topicName=抗病毒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fde12143369, createdName=Eleven15, createdTime=Tue Aug 02 10:30:06 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235900, encodeId=e1b51235900f2, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Aug 01 11:20:41 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235862, encodeId=43a0123586208, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:12:11 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235858, encodeId=6e321235858b9, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/29/f48081e2c7622ec35cbcc4345041d752.jpg, createdBy=0e865110940, createdName=涧西源长, createdTime=Mon Aug 01 09:07:19 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-01 涧西源长

    真好

    0

相关资讯

NEJM:新冠病毒感染后能持续传播病毒多久?

据国家卫健委网站6月28日消息,国务院联防联控机制发布第九版新冠肺炎防控方案,将密切接触者、入境人员隔离管控时间从“14天集中隔离医学观察+7天居家健康监测”调整为&ldquo

NEJM Evid:口服Sabizabulin 治疗成人重度Covid-19感染的期中分析,能减少死亡55%

Sabizabulin是一款前列腺癌靶向药,其本质是一种微管蛋白抑制剂。微管是细胞骨架结构的组成部分,由两种球状蛋白(α和β微管蛋白)的二聚体聚合而成,微管在许多细胞过程中非常重

羟氯喹与新冠:永无止尽的故事

在 COVID-19 大流行的早期,迫切需要一种治疗方法来对抗正在摧毁全球医疗保健系统的祸害。随着系统不堪重负,很明显需要有效、安全、可及的早期门诊治疗以防止恶化。

PNAS:新冠病毒在气溶胶中,20分钟会失去90%传染性

根据布里斯托大学的新发现,SARS-CoV-2 病毒在气溶胶颗粒中 20 分钟内会失去 90% 的传染性。 该研究发表在《美国国家科学院院刊》(PNAS) 杂志上,首次调查了气溶胶颗粒中 SARS-C

常温下物体表面新冠病毒1天内全部失活!无需对海淘、快递产品等消杀

近日,很多人关注到国家卫健委官网7月12日发布的《关于进一步优化进口物品新冠肺炎疫情防控工作的通知》(以下简称《通知》)。根据该《通知》,各地不再对进口非冷链物品进行新冠病毒核酸检测,因为最新研究显示

J Virol:新冠病毒为什么不会把蝙蝠搞死?

虽然,目前新冠病毒来源并不完全清楚,但一般认为蝙蝠可能是主要宿主。这里有两个问题: